Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

BACKGROUND: Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overall patient outcomes. Ocrelizumab, a recombinant humanized m...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirks, Petra, Zingler, Vera, Leemhuis, Jost, Berthold, Heike, Hieke-Schulz, Stefanie, Wormser, David, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071560/
https://www.ncbi.nlm.nih.gov/pubmed/32171264
http://dx.doi.org/10.1186/s12883-020-01667-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071560/
https://www.ncbi.nlm.nih.gov/pubmed/32171264
http://dx.doi.org/10.1186/s12883-020-01667-7

Ejemplares similares